Subcutaneous injection of infliximab CT-P13 results in stable drug levels within 14-day treatment cycle in Crohn's disease.
Xavier RoblinPauline VeyrardLaetitia BastideAnne E BergerMathilde BarrauAnne-Sophie PaucelleLouis WaeckelSany KwiatekBernard FlourieStephane NanceyStephane PaulPublished in: Alimentary pharmacology & therapeutics (2022)
IFX drug levels are quite stable within 14-day treatment cycle, without trough levels in CD patients in remission during the maintenance therapy with CT-P13 sc. In patients with inactive CD under maintenance therapy with CT-P13 sc, therapeutic drug monitoring of IFX can be performed at any time between two CT-P13 sc injections.
Keyphrases
- image quality
- dual energy
- computed tomography
- contrast enhanced
- end stage renal disease
- positron emission tomography
- chronic kidney disease
- stem cells
- prognostic factors
- peritoneal dialysis
- magnetic resonance
- combination therapy
- replacement therapy
- bone marrow
- systemic lupus erythematosus
- disease activity
- electronic health record